(Q46922239)

English

Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy

scientific article published on 13 December 2013

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24338277

Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24338277

0 references

1 reference

based on heuristic

inferred from title

2

object named as

Ian F Tannock

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24338277

author name string

Jasdeep K Saggar

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24338277

language of work or name

0 references

publication date

13 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24338277

number of pages

9

1 reference

based on heuristic

inferred from page(s)

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24338277

134

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24338277

11

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24338277

2726-2734

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24338277

Exploiting tumour hypoxia in cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

Drug penetration in solid tumours

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

Targeting hypoxia in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

Explicit hypoxia targeting with tumor suppression by creating an "obligate" anaerobic Salmonella Typhimurium strain

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

Tirapazamine: a novel agent targeting hypoxic tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

Use of molecular biomarkers to quantify the spatial distribution of effects of anticancer drugs in solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

Use of a carbocyanine dye as a marker of functional vasculature in murine tumours

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

Ordering of caspases in cells undergoing apoptosis by the intrinsic pathway

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

Quantitative immunohistochemistry for evaluating the distribution of Ki67 and other biomarkers in tumor sections and use of the method to study repopulation in xenografts after treatment with paclitaxel

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

Superoxide accelerates DNA damage by elevating free-iron levels

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28595

21 January 2018

Identifiers

10.1002/IJC.28595

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24338277

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24338277

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46922239&oldid=2137942193"